CA2903072C - Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition, and use thereof - Google Patents

Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition, and use thereof Download PDF

Info

Publication number
CA2903072C
CA2903072C CA2903072A CA2903072A CA2903072C CA 2903072 C CA2903072 C CA 2903072C CA 2903072 A CA2903072 A CA 2903072A CA 2903072 A CA2903072 A CA 2903072A CA 2903072 C CA2903072 C CA 2903072C
Authority
CA
Canada
Prior art keywords
oxa
azabicyclo
compound
title compound
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2903072A
Other languages
English (en)
French (fr)
Other versions
CA2903072A1 (en
Inventor
Jingkang Shen
Ke Yu
Tao Meng
Lanping Ma
Arie Zask
Lanfang MENG
Xin Wang
Yiyi CHEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica
Shandong Luoxin Pharmaceutical Group Co Ltd
Fudan University
Original Assignee
Shanghai Institute of Materia Medica
Shandong Luoxin Pharmaceutical Group Co Ltd
Fudan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica, Shandong Luoxin Pharmaceutical Group Co Ltd, Fudan University filed Critical Shanghai Institute of Materia Medica
Publication of CA2903072A1 publication Critical patent/CA2903072A1/en
Application granted granted Critical
Publication of CA2903072C publication Critical patent/CA2903072C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2903072A 2013-03-04 2014-02-28 Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition, and use thereof Active CA2903072C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201310068888.8A CN103588792B (zh) 2013-03-04 2013-03-04 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途
CN201310068888.8 2013-03-04
PCT/CN2014/072678 WO2014135028A1 (zh) 2013-03-04 2014-02-28 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途

Publications (2)

Publication Number Publication Date
CA2903072A1 CA2903072A1 (en) 2014-09-12
CA2903072C true CA2903072C (en) 2019-05-07

Family

ID=50079144

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2903072A Active CA2903072C (en) 2013-03-04 2014-02-28 Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition, and use thereof

Country Status (11)

Country Link
US (1) US9796732B2 (enExample)
EP (1) EP2966079B1 (enExample)
JP (1) JP2016510042A (enExample)
CN (1) CN103588792B (enExample)
AU (1) AU2014225155B2 (enExample)
CA (1) CA2903072C (enExample)
DE (1) DE14760712T1 (enExample)
DK (1) DK2966079T3 (enExample)
ES (1) ES2572105T3 (enExample)
RU (1) RU2662713C2 (enExample)
WO (1) WO2014135028A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103588792B (zh) * 2013-03-04 2016-03-23 中国科学院上海药物研究所 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途
CN106008559B (zh) * 2015-03-25 2020-10-16 中国科学院上海药物研究所 取代吡啶并嘧啶类化合物的合成工艺
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2019091400A1 (zh) * 2017-11-07 2019-05-16 中国科学院上海药物研究所 吡啶并嘧啶类化合物的盐型和晶型及其制备方法
CN109867667B (zh) * 2017-12-05 2021-06-11 中国药科大学 含有吡啶并嘧啶结构的parp和pi3k双靶点抑制剂
CN113825760B (zh) * 2019-05-06 2022-08-19 南京明德新药研发有限公司 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法
WO2021247859A1 (en) * 2020-06-03 2021-12-09 Yumanity Therapeutics, Inc. Pyridopyrimidines and methods of their use
WO2022061251A1 (en) * 2020-09-18 2022-03-24 Plexxikon Inc. Compounds and methods for kras modulation and indications therefor
CN115260158A (zh) * 2021-04-30 2022-11-01 上海医药集团股份有限公司 一种靶向蛋白调节剂的化合物及其应用
WO2023018812A1 (en) * 2021-08-10 2023-02-16 Amgen Inc. Heterocyclic compounds and methods of use
JP2024532735A (ja) * 2021-08-10 2024-09-10 アムジエン・インコーポレーテツド 複素環式化合物及び使用方法
US20240417412A1 (en) * 2021-08-10 2024-12-19 Amgen Inc. Heterocyclic compounds and methods of use
JP2025519743A (ja) * 2022-06-15 2025-06-26 ミラティ セラピューティクス， インコーポレイテッド 汎ＫＲａｓ阻害剤のプロドラッグ
WO2024057013A1 (en) * 2022-09-12 2024-03-21 Exscientia Ai Limited Nlrp3 modulators
CN117586255A (zh) * 2023-09-25 2024-02-23 上海图芃生物科技有限公司 一种口服atp竞争性激酶抑制剂及其合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007010401A (es) * 2005-02-25 2008-02-19 Kudos Pharm Ltd Derivados de 2,4-diamino-piridopirimidina y su uso como inhbidores de mtor.
UA96745C2 (en) * 2005-11-22 2011-12-12 Кудос Фармасьютикалз Лимитед PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
AU2007282535B9 (en) * 2006-08-08 2013-06-20 Chugai Seiyaku Kabushiki Kaisha Pyrimidine derivative as PI3K inhibitor and use thereof
CN101558067B (zh) * 2006-08-23 2014-05-28 库多斯药物有限公司 作为mtor抑制剂的2-甲基吗啉吡啶并、吡唑并和嘧啶并-嘧啶衍生物
US20080233127A1 (en) * 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
WO2010120987A1 (en) * 2009-04-17 2010-10-21 Wyeth Llc Ring fused, ureidoaryl- and carbamoylaryl-bridged morpholino-pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
CN102887895B (zh) * 2011-07-22 2016-08-24 山东轩竹医药科技有限公司 吡啶并嘧啶类mTOR抑制剂
CN102911172A (zh) * 2011-08-04 2013-02-06 上海恒瑞医药有限公司 杂芳基并嘧啶类衍生物、其制备方法和用途
CN103588792B (zh) * 2013-03-04 2016-03-23 中国科学院上海药物研究所 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途

Also Published As

Publication number Publication date
US20150368274A1 (en) 2015-12-24
DK2966079T1 (da) 2016-05-17
EP2966079A1 (en) 2016-01-13
EP2966079B1 (en) 2021-11-24
CN103588792B (zh) 2016-03-23
RU2662713C2 (ru) 2018-07-27
HK1217197A1 (en) 2016-12-30
RU2015140387A (ru) 2017-03-30
AU2014225155B2 (en) 2017-11-23
DK2966079T3 (da) 2022-02-14
CA2903072A1 (en) 2014-09-12
AU2014225155A1 (en) 2015-10-15
ES2572105T3 (es) 2022-04-13
ES2572105T1 (es) 2016-05-30
WO2014135028A1 (zh) 2014-09-12
DE14760712T1 (de) 2017-12-14
US9796732B2 (en) 2017-10-24
CN103588792A (zh) 2014-02-19
JP2016510042A (ja) 2016-04-04
EP2966079A4 (en) 2016-11-09

Similar Documents

Publication Publication Date Title
EP2966079B1 (en) Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition and use thereof
RU2747260C2 (ru) Ингибитор рфрф4, способ его получения и его фармацевтическое применение
US20240270753A1 (en) Heterocyclic compound for inhibiting shp2 activity, preparation method therefor and use thereof
WO2021121397A1 (zh) 取代的炔基杂环化合物
TW202321261A (zh) 選擇性ｋｒａｓ抑制劑
US20220289719A1 (en) Heterocyclic compounds as mnk inhibitors
CN101932584A (zh) 作为pi3k阻滞剂的吡咯并嘧啶衍生物及其用途
CA2883426A1 (en) Pyrrolotriazinone derivatives as pi3k inhibitors
CN110621675A (zh) 用于治疗增殖性疾病的三环化合物
ES2529205T3 (es) Derivados de pirimidina como inhibidores de mTOR
CN115677730B (zh) 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途
JP2018135268A (ja) 新規ヘテロアリールアミノ−３−ピラゾール誘導体およびその薬理学上許容される塩
CN104557871A (zh) 具有螺环取代基的芳基吗啉类化合物，其制备方法和用途
CN104557913B (zh) 吡啶并嘧啶类化合物，其制备方法和用途
CN113004282A (zh) 取代的炔基杂环化合物
US20240101535A1 (en) Dihydroisoquinolinone derivative and application thereof
CN103534252B (zh) 苯并吗啉衍生物及其制备方法和应用
US20250382301A1 (en) Small molecule inhibitors of dyrk/clk and uses thereof
HK1217197B (en) Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition and use thereof
CN113880842A (zh) 取代的炔基杂环化合物
WO2013144532A1 (en) 3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
CA3092149C (en) Indolizine compound, preparation method and use thereof
EP4671245A1 (en) HETEROAROMATIC CYCLIC COMPOUND SERVING AS A CDK7 KINASE INHIBITOR, ITS PREPARATION AND USE
NZ787350A (en) Heterocyclic compounds as ret kinase inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160817

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250828

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251110